Search Within
Document Type
87-99-0
Applied Filters:
Keyword:'87-99-0'
Showing 1-30 of 320 results for "87-99-0" within Technical Documents
The Effective Use of Protein Kinase Inhibitors
98 101 72 35 108 99 100 21 63 26
S6K1 0 94 32 98 93 92 86 100 87 75 106 81 25 109 95 101 6 32 18
GSK-3β 107 92 90 13 38 105 83
The Effective Use of Protein Kinase Inhibitors
98 101 72 35 108 99 100 21 63 26
S6K1 0 94 32 98 93 92 86 100 87 75 106 81 25 109 95 101 6 32 18
GSK-3β 107 92 90 13 38 105 83
PureFlex FILM: Extractables Bioreactivity Safety Evaluation Approach
calculations
• USP 87> and testing of un-aged and aged
samples was conducted by an accredited laboratory for
USP biological testing.
• USP 87>: Elution Method
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
00
0
7,
00
0
8,
00
0
9,
00
0
0
50
,0
00
10
0,
00
0
15
0,
00
0
20
0,
00
0
25
0,
00
0
30
0,
00
010 10
0
1,
00
0
10
,0
00
10
0,
00
0
10 10
0
1,
00
0
10
,0
00
Flow-Through Removal of mAb Aggregates with Eshmuno®CP-FT Resin
CEX bind/elute Eshmuno® CPX 80 87% 0.42% 0% 0.42% 3 15.8
3. AEX flow-through Eshmuno® Q 150 >99% 0.43% 0% 0.43% 1 3.1
2. CEX flow-through Eshmuno® CP-FT 1000 92% 0.55% 0% 0.55% 17 13.6
3. AEX
LABORATORY NOTEBOOK ISSUANCE PAGE
tg
en
iu
m
10
.8
1
12
.0
11
14
.0
07
15
.9
99
18
.9
98
20
.1
80
4.
00
26
26
.9
82
28
.0
85
30
.9
74
32
.0
6
35
.4
LABORATORY NOTEBOOK ISSUANCE PAGE
tg
en
iu
m
10
.8
1
12
.0
11
14
.0
07
15
.9
99
18
.9
98
20
.1
80
4.
00
26
26
.9
82
28
.0
85
30
.9
74
32
.0
6
35
.4
Poster: Purification with Millipore MultiScreen 384SEQ Plates on Beckman-Coulter’s Biomek FX for High Quality Direct Sequencing in High-Throughput Genomics
Average Phred 37 37 39
Average >
Phred 30
Readlength 323 321 353
% Pass Rate* 87% 83% 94%
# of
Resequenced
Plates** 7 8 0
*Pass rate = number of samples with Phred score > 30 and at least 100
bp of
LABORATORY NOTEBOOK ISSUANCE PAGE
tg
en
iu
m
10
.8
1
12
.0
11
14
.0
07
15
.9
99
18
.9
98
20
.1
80
4.
00
26
26
.9
82
28
.0
85
30
.9
74
32
.0
6
35
.4
Neutralization Efficacy of ICR Contact Plates App Note
neutralization of active residues.
120
98
56
97
112
102 101
80
87
159
98
87
69
101
118
0
20
40
60
80
100
120
Eshmuno® Q Resin for Efficient AEX Chromatography
47 15.1
2. CEX
flow-through
Eshmuno® CP-FT 1000 92% 0.55% 0% 0.55% 17 13.6
3. AEX
flow-through
Eshmuno® Q 150 >99% 0.61% 0% 0.61% 3 8.7
mAb 02
HCP in
supernatant
Neutralizing Efficiency of Lecithin and Polysorbate 80 in ICR Contact Plates and Swabs for Surface Monitoring
102
89
104
111
85
97
80
109
99
84
91
117
101
108
99
109
99
128
87
108
83
92 95 93
159
126 125
0
Monitoring low dose API blend uniformity with Parteck® M
69 75 81 87 93 99
Lab data
Calibration Set: Calculated vs Lab Data
105 111 117 123 129 135
129
135
123
117
111
105
99
M
od
el
p
re
di
ct
ed
d
at
MultiScreen Assay System for High Throughput Cell-based Transport
Ratio 10 day 21 day 10 day 21 day
Digoxin 11.5 30.5 6.6 14.5
% LY rejection AP/BL 99 >99 98 >99
Optimized Plate Design Improves Dynamic
Application Note – N-Boc protection
96%
96%96%
99%
Boc
Boc
Boc
Boc
Boc
BocBoc
N
H
CF3
N CF3
HO
N
99%
96%
HO
O
O
N
H
N
H
Me
OH
96% 98%
Protocol- EZMCP1-99KRM|EZMCP1-99K5PKRM|EZMCP1-99K10PKRM
79.4 87
125 137.8 90
Plasma 4 0 21.6
31.25 50.3 92
62.5 75.7 87
125 131.6 88
Plasma 5 0 15.9
User Guide - Amicon® Ultra-2 Centrifugal Filter Devices
71 203 10
15 60 33 37 57 22 90 61 34
20 215 10 39 51 24 85 21 99 32 63
30 106 19 25 80 20 101 18 89 17 115
40 70
User Guide-RAB1062
Serum 95 86-101
Plasma 87 79-95
Cell Culture Supernatants 87 78-95
Linearity
Sample Type Serum Plasma Cell Culture Supernatants
1:2
Average % of Expected 87 87 96
Range (%) 79-95 79-94
Amicon® Ultra-2 Centrifugal Filter Devices Non IVD User guide
71 203 10
15 60 33 37 57 22 90 61 34
20 215 10 39 51 24 85 21 99 32 63
30 106 19 25 80 20 101 18 89 17 115
40 70
S(–)-Blebbistatin: Selective inhibitor ofnon-muscle myosin II
Scand. J. Immunol., 56, 66-75 (1995).
98, Yoshida, K., et al., Proc. Natl. Acad. Sci. USA, 99, 4580-4585 (2002).
99. Hong, M. et al., Circulation, 104, 1176-1180 (2001).
100. Nantel, F. et al., “Altered bronchodilation
Human MCP-1 ELISA
Plasma 1 0 23.0
31.25 51.0 90
62.5 69.9 75
125 128.2 84
Plasma 2 0 18.9
Scalability of Mobius®Single-Use Bioreactors
94
95
96
97
98
99
100
0 2 4 6 8 10 12
%
V
ia
bi
lit
y
V
ia
bl
e
C
el
l D
en
si
ty
Periodic table A4
Unknown title
S
ta
n
d
:
0
1
/2
0
1
7
W
.2
8
0
7
1
8
The life science business of Merck
Product Information Sheet-04693116001
incubation
with the protease
Pancreas extract 0.015 7.8 87 99
0.03 6.5 88 96
Pronase 0.0015 7.8 88 99
0.003 7.0 90 95
Thermolysin 0.0008 7.8 99 100
Chymotrypsin 0.0015 7.8 97 97
Trypsin 0.0002 7.8 93
Product Information Sheet - A6144
.V. et al., Analytical Biochem., 120, 176 (1982).
7. Tornheim K. et al., Analytical Biochem., 103, 87 (1980).
8. Wilson, J.E. and Chin A., Analytical Biochem., 193, 16 (1991).
9. Solheim, L.P. and Fromm
Product Information Sheet - A5394
.V. et al., Analytical Biochem., 120, 176 (1982).
7. Tornheim K. et al., Analytical Biochem., 103, 87 (1980).
8. Wilson, J.E. and Chin A., Analytical Biochem., 193, 16 (1991).
9. Solheim, L.P. and Fromm
Data Sheet - S3065
- Datasheet
SC 19220
Product Number S 3065
Storage Temperature RT
Cas #: 19395-87-0
Synonyms: 8–Chloro–dibenz[b,f][1,4]oxazepine-
10(11H)–carboxylic acid 2–acetylhydrazide
O
Protocol- EZHTNFA-150K
4.9 9.4 102
14.8 19.0 99
44.7 47.5 97
Serum 5 0 3.7
4.9 8.0 87
14.8 16.4 86
44.7 41.4 85
Average 95
S
am
pl
e
User Guide - EZHTNFA
4.9 9.4 102
14.8 19.0 99
44.7 47.5 97
Serum 5 0 3.7
4.9 8.0 87
14.8 16.4 86
44.7 41.4 85
Average 95
S
am
pl
e
Understanding the Effect of Discreet PEG Linkers on ADC Structure and Binding
FcRn
KD (nM) Rel. KD (%) KD (nM) Rel. KD (%) KD (nM) Rel. KD (%)
Reference 0 169 100 468 100 392 100
LC-SMCC 4.1 195 87 465 101 309 128
PEG4 4.1 211 80 500 94 299 132
PEG8 4.0 200
Page 1 of 11